Academic Journal
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
| العنوان: | Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer |
|---|---|
| المؤلفون: | Viale, G., Giobbie-Hurder, A., Gusterson, B. A., Maiorano, E., Mastropasqua, M. G., Sonzogni, A., Mallon, E., Colleoni, M., Castiglione-Gertsch, M., Regan, M. M., Price, K. N., Brown, R. W., Golouh, R., Crivellari, D., Karlsson, P., Öhlschlegel, C., Gelber, R. D., Goldhirsch, A., Coates, A. S. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2010 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | breast cancer |
| الوصف: | Background: Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer. Patients and methods: Patients participated in two International Breast Cancer Study Group randomized trials testing chemoendocrine adjuvant therapies in premenopausal (trial VIII) or postmenopausal (trial IX) node-negative breast cancer. PVI was assessed by institutional pathologists and/or central review on hematoxylin–eosin-stained slides in 99% of patients (analysis cohort 2754 patients, median follow-up >9 years). Results: PVI, present in 23% of the tumors, was associated with higher grade tumors and larger tumor size (trial IX only). Presence of PVI increased locoregional and distant recurrence and was significantly associated with poorer disease-free survival. The adverse prognostic impact of PVI in trial VIII was limited to premenopausal patients with endocrine-responsive tumors randomized to therapies not containing goserelin, and conversely the beneficial effect of goserelin was limited to patients whose tumors showed PVI. In trial IX, all patients received tamoxifen: the adverse prognostic impact of PVI was limited to patients with receptor-negative tumors regardless of chemotherapy. Conclusion: Adequate endocrine adjuvant therapy appears to abrogate the adverse impact of PVI in node-negative disease, while PVI may identify patients who will benefit particularly from adjuvant therapy. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://annonc.oxfordjournals.org/cgi/content/short/21/2/245; http://dx.doi.org/10.1093/annonc/mdp317 |
| DOI: | 10.1093/annonc/mdp317 |
| الاتاحة: | http://annonc.oxfordjournals.org/cgi/content/short/21/2/245 https://doi.org/10.1093/annonc/mdp317 |
| Rights: | Copyright (C) 2010, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.545490AF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mdp317 |
|---|